Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Markella V. Zanni, M.D.

Co-Author

This page shows the publications co-authored by Markella Zanni and Steven Grinspoon.
Connection Strength

10.458
  1. Striving to characterize endocrine-metabolic and immune health risks among transgender women with HIV. AIDS. 2019 04 01; 33(5):919-922.
    View in: PubMed
    Score: 0.832
  2. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis. 2017; 4(4):ofx227.
    View in: PubMed
    Score: 0.752
  3. Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis. 2017 04 15; 215(8):1264-1269.
    View in: PubMed
    Score: 0.726
  4. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. JAMA Cardiol. 2016 07 01; 1(4):474-80.
    View in: PubMed
    Score: 0.688
  5. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70.
    View in: PubMed
    Score: 0.607
  6. HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque. Antivir Ther. 2014; 19(8):805-811.
    View in: PubMed
    Score: 0.584
  7. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS. 2013 May 15; 27(8):1263-72.
    View in: PubMed
    Score: 0.554
  8. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf). 2012 Sep; 77(3):385-90.
    View in: PubMed
    Score: 0.527
  9. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep. 2012 Sep; 9(3):200-5.
    View in: PubMed
    Score: 0.527
  10. Effects of TNF-alpha antagonism on E-selectin in obese subjects with metabolic dysregulation. Clin Endocrinol (Oxf). 2010 Jul; 73(1):48-54.
    View in: PubMed
    Score: 0.454
  11. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2021 02 03; 223(2):352.
    View in: PubMed
    Score: 0.236
  12. Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa459.
    View in: PubMed
    Score: 0.231
  13. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. J Infect Dis. 2020 08 17; 222(6):929-939.
    View in: PubMed
    Score: 0.229
  14. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S63-S69.
    View in: PubMed
    Score: 0.227
  15. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S20-S30.
    View in: PubMed
    Score: 0.227
  16. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 06; 212:23-35.
    View in: PubMed
    Score: 0.207
  17. Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. AIDS. 2019 02 01; 33(2):229-236.
    View in: PubMed
    Score: 0.206
  18. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018 Sep; 35:58-66.
    View in: PubMed
    Score: 0.200
  19. Novel mediators of statin effects on plaque in HIV: a proteomics approach. AIDS. 2018 04 24; 32(7):867-876.
    View in: PubMed
    Score: 0.195
  20. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017 03 27; 31(6):797-806.
    View in: PubMed
    Score: 0.181
  21. Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. HIV Clin Trials. 2017 03; 18(2):83-91.
    View in: PubMed
    Score: 0.180
  22. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS. 2016 09 10; 30(14):2205-14.
    View in: PubMed
    Score: 0.174
  23. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. AIDS. 2016 Jan 28; 30(3):383-93.
    View in: PubMed
    Score: 0.167
  24. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol. 2014 Dec; 11(12):728-41.
    View in: PubMed
    Score: 0.153
  25. Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Jun 01; 66(2):164-71.
    View in: PubMed
    Score: 0.149
  26. Increased FDG uptake in association with reduced extremity fat in HIV patients. Antivir Ther. 2013; 18(2):243-8.
    View in: PubMed
    Score: 0.133
  27. Arterial inflammation in patients with HIV. JAMA. 2012 Jul 25; 308(4):379-86.
    View in: PubMed
    Score: 0.131
  28. Estrogen sulfotransferase is expressed in subcutaneous adipose tissue of obese humans in association with TNF-alpha and SOCS3. J Clin Endocrinol Metab. 2011 Jul; 96(7):E1153-8.
    View in: PubMed
    Score: 0.120
  29. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011 Jan; 96(1):E146-50.
    View in: PubMed
    Score: 0.116
  30. Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 Jun 16.
    View in: PubMed
    Score: 0.061
  31. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 Jun 01; 4(6):e2114923.
    View in: PubMed
    Score: 0.060
  32. Increased CHIP Prevalence Amongst People Living with HIV. medRxiv. 2020 Nov 07.
    View in: PubMed
    Score: 0.058
  33. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis. 2020 07 09; 222(Suppl 1):S31-S40.
    View in: PubMed
    Score: 0.057
  34. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S8-S19.
    View in: PubMed
    Score: 0.057
  35. Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. HIV Res Clin Pract. 2020 02; 21(1):11-23.
    View in: PubMed
    Score: 0.056
  36. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity (Silver Spring). 2020 04; 28(4):749-755.
    View in: PubMed
    Score: 0.055
  37. Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort. Arterioscler Thromb Vasc Biol. 2019 09; 39(9):1762-1775.
    View in: PubMed
    Score: 0.053
  38. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 06; 212:1-12.
    View in: PubMed
    Score: 0.052
  39. Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals. Open Forum Infect Dis. 2018 Dec; 5(12):ofy326.
    View in: PubMed
    Score: 0.051
  40. Elevated ischemic stroke risk among women living with HIV infection. AIDS. 2018 Jan 02; 32(1):59-67.
    View in: PubMed
    Score: 0.048
  41. HDL Cholesterol Efflux Capacity in Newly Diagnosed HIV and Effects of Antiretroviral Therapy. J Clin Endocrinol Metab. 2017 11 01; 102(11):4250-4259.
    View in: PubMed
    Score: 0.047
  42. Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. Circ Cardiovasc Imaging. 2017 10; 10(10).
    View in: PubMed
    Score: 0.047
  43. Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus. Open Forum Infect Dis. 2017; 4(2):ofx083.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.